Cost Benefit Study Supports the Use of Longport's Technology in Pressure Ulcer Prevention
30 Avril 2007 - 2:30PM
Business Wire
Longport, Inc. (OTC PK: LPTI), a medical technology specialist in
high-frequency high resolution ultrasound imaging, today announced
interim results from a cost benefit study supporting the use of its
EPISCAN I-200 system as an evidence based pressure ulcer prevention
tool. Study results showed an expected cost-savings per at-risk
resident of $5,341.00 per year with use of the EPISCAN in concert
with current practice standards for pressure ulcer prevention when
compared to current pressure ulcer prevention measures alone.
Statistical Analysis using Monte Carlo simulation showed the use of
the EPISCAN Ultrasound diagnosis to be the preferred option 73.7%
of the time and that the decision to use the EPISCAN was very
robust and changed only when the incidence of pressure ulceration
was below 3.0% in the standard evidence-based group. The study,
which is still on-going, is being undertaken at an extended care
rehabilitation nursing home in upstate New York. These interim
findings are being presented by Ron Shannon, the principal
investigator at the Symposium on Advanced Wound Care (SAWC) and The
Wound Healing Society (WHS) meeting in Tampa, Florida (April 28 �
May 1, 2007). Mr. Shannon said, �The timing is right for a
cost-effective, diagnostic tool that will give early insight into
non-visible pressure ulcer injury so treatment and prevention can
begin early. The morbidity associated with the development of
pressure ulcers increases patient suffering, nurses� workload and
risk of death. Pressure ulcers also increase the length of stay and
resultant expense of hospitalization, hardly affordable
consequences in today�s era of health care economics. We conclude
that the EPISCAN, in extended care rehabilitation units, is a
cost-benefit to providers for preventing costly pressure ulcers.�
Connie Phillips-Jones, RN, MSN, Director of Clinical Support, said,
�This is an exciting conclusion and supports the use of the EPISCAN
I-200 and will contribute to clinical acceptance based on
evidence.� Further details on this presentation and other clinical
study papers can be viewed at the News section of Longport�s WEB
site. http://www.longportinc.com/about/news.html About Longport,
Inc. Longport, Inc. of Glen Mills, Pennsylvania, is a medical
technology company that specializes in high resolution ultrasound
imaging. After several years and a multi-million dollar investment
in the technology, Longport has secured patents, copyrights and FDA
permission to market. The Company�s technology has been used to
engineer a unique high resolution ultrasound imaging system. For
further information please contact Longport, Inc. at 1-800-289-6863
or visit our website at www.longportinc.com. Forward-looking
Information and the Private Securities Litigation Reform Act of
1995 Certain statements in this press release, including statements
concerning product development milestones and anticipated events,
are �forward-looking statements� within the Private Litigation
Reform Act of 1995. Forward Looking Statements are based on the
opinions and estimates of management at the time the statements are
made and are subject to certain risks and uncertainties that could
cause actual results to differ materially from those anticipated in
the forward-looking statements. The words �believe,� �expect,�
�intend,� �anticipate,� variations of such words, and similar
expressions identify forward-looking statements, but their absence
does not mean that the statement is not forward-looking. These
statements are not guarantees of future performance and are subject
to certain risks, uncertainties and assumptions that are difficult
to predict. Factors that could affect Longport�s actual results
include, among others, uncertainties as to the Company�s ability to
manage potential problems, delays or anticipated expenses,
including problems, delays or expenses involving manufacturing.
Readers are cautioned not to place undue reliance upon these
forward-looking statements that speak only to the date of this
release. Reference is made to Longport�s 2004 annual report on Form
10-K filed with the Securities and Exchange Commission for a more
definitive description of such factors. Longport, Inc. undertakes
no obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date of
this release or to reflect the occurrence of unanticipated events.
Longport (CE) (USOTC:LPTI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Longport (CE) (USOTC:LPTI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
Real-Time news about Longport Inc (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Longport, Inc.